-
Shares of MannKind Plummet Prior to Drug Advisory Meeting
Monday, March 31, 2014 - 3:46pm | 323Shares of MannKind Corp. (NASDAQ: MNKD) fall as much as 27.105% prior to Tuesday's Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Piper Jaffray analyst Joshua Schimmer noted that MannKind faces a "number of obstacles" in the U.S. Food and Drug Administration's (FDA) review of...
-
Summer Street Reports Concerns Over Afrezza Affinity 1 Studies
Thursday, March 27, 2014 - 3:05pm | 230Shares of MannKind (NASDAQ: MNKD) are down approximately 2 percent amid comments from Summer Street analyst Bart Classen. Classen reported in an interview that MannKind's briefing documents may be “problematic” regarding Affinity 1 studies on the Afrezza Dreamboat insulin inhaler. The analyst...
-
ARIAD Resumes Marketing and Distribution of Iclusig, Investors Getting Some Relief
Friday, December 20, 2013 - 2:25pm | 766Shares of Ariad Pharmaceuticals (NASDAQ: ARIA) responded following an early Friday formal announcement that the company has U.S. approval to bring Inclusig back to the market, and will begin to sell by mid- January. Ariad shares hit $7.75, up 40 percent. Ariad said, "The USPI includes a revised...
-
Avanir Shares Rebound As Analysts Offer Defense On Heels of 13% Drop
Thursday, September 12, 2013 - 4:26pm | 246Avanir Pharmeceuticals (NASDAQ: AVNR) stock plummeted yesterday after Gravity Research said Avanir, “engaged in illegal off-label marketing of Nuedexta,” and recommended a strong Sell. Shares closed at $4.79 on Wednesday, a 13 percent decrease. This was the biggest drop of AVNR in three years...
-
UPDATE: Summer Street Initiates Lpath Incorporated at Buy on Valuation
Thursday, December 27, 2012 - 12:11pm | 98Summer Street initiated coverage on Lpath Incorporated (NASDAQ: LPTN) with a Buy rating and an $18 price target. Summer Street noted, "Lpath's valuation is compelling when compared to other platform companies in similar positions. Our iSONEP royalty projections begin in 2017 at $28MM and grow to...
-
UPDATE: Summer Street Initiates Dendreon with Buy, $18 PT on Entry Opportunity
Wednesday, June 13, 2012 - 1:42pm | 113Summer Street initiates its coverage on Dendreon (NASDAQ: DNDN) with a Buy rating and a $18 price target. Summer Street comments, "DNDN's stock has declined >80% since the company announced slower than expected Provenge adoption and lowered prior 2011 revenue guidance during the 2Q11 earnings...
-
UPDATE: Summer Street Initiates Coverage on Synergy Pharmaceuticals
Thursday, March 22, 2012 - 3:00pm | 102According to a research report published earlier today, Summer Street has initiated Synergy Pharmaceuticals (NASDAQ: SGYP) with a Buy rating and $9 PT. Summer Street said in the report, “We believe SGYP's lead compound, plecanatide, has great potential to become the second, but best-inclass,...
-
Hearing Medivation Initiated with Buy at Summer Street
Tuesday, October 18, 2011 - 9:08am -
Summer Street Downgrades Wright Medical From Neutral To Sell
Wednesday, April 6, 2011 - 9:08am | 20Summer Street has downgraded Wright Medical (NASDAQ: WMGI) from Neutral to Sell.